Celltrion Pharm Inc
The 068760-KQ stock trades on Korea Exchange Kosdaq
Celltrion Healthcare conducts worldwide marketing, sales, and distribution of biological medicines through an extensive global network that spans more than 120 different countries. Celltrion Healthcare provides REMSIMA, the world's first biosimilar monoclonal antibody (mAb) approved by the European Medicines Agency (EMA) for the treatment of autoimmune disease, and innovative biopharmaceutical medications to help increase patient access to advanced therapies around the world.
Source: Celltrion Pharm Inc - 20220920
Chronic Lymphocytic Leukemia
Wegener's Granulomatosis and Microscopic Polyangiitis
RecruitingA Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Me...
Impact of l-Carnitine Supplementation on Liver Enzyme Normalization in Patients with Chronic Liver Disease: A Meta-Analysis of Ran...
Clinical Significance of Antineutrophil Cytoplasmic Antibody Positivity in Patients Infected with SARS-CoV-2
Serum glycated albumin as a predictive biomarker for renal involvement of antineutrophil cytoplasmic antibody-associated vasculiti...
Soluble immune checkpoint molecules in patients with antineutrophil cytoplasmic antibody-associated vasculitis
Prolonged Use of Carnitine-Orotate Complex (Godex®) Is Associated with Improved Mortality: A Nationwide Cohort Study
0 Comments on 068760-KQ stock